Haugeberg Glenn, Bøyesen Pernille, Helgetveit Knut, Prøven Anne
From the Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand; Norwegian University of Science and Technology, Trondheim; Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway.G. Haugeberg, MD, PhD, consultant, Department of Rheumatology, Hospital of Southern Norway Trust, professor, Norwegian University of Science and Technology; P. Bøyesen, MD, PhD, assistant doctor, Department of Rheumatology, Diakonhjemmet Hospital; K. Helgetveit, MD, Department of Rheumatology, Martina Hansens Hospital; A. Prøven, MD, Department of Rheumatology, Martina Hansens Hospital.
J Rheumatol. 2015 Dec;42(12):2279-87. doi: 10.3899/jrheum.150384. Epub 2015 Nov 15.
To study short-term and longterm clinical and radiographic outcomes in patients with early rheumatoid arthritis (RA) in the first decade of the biologic treatment era.
Patients with early RA diagnosed at a rheumatology outpatient clinic were consecutively enrolled between 1999 and 2001. Data were collected on demographic characteristics, disease activity, patient-reported outcomes, and treatments. Radiographs of hands and feet were performed at baseline and after 2, 5, and 10 years and scored according to the Sharp/van der Heijde method, yielding a modified total Sharp score (mTSS).
Mean baseline age for the 94 included patients (36 men and 58 women) was 50.4 years and symptom duration 12.3 months; 67.8% were rheumatoid factor-positive. The proportion of patients in remission and in low, moderate, and high disease activity status was at baseline 4.3%, 1.1%, 35.1%, and 59.6% and at 10 years 52.1%, 20.5%, 27.4%, and 0.0%, respectively. For the period 0-2 years, 62.8% had used prednisolone, 91.5% synthetic disease-modifying antirheumatic drug (DMARD), and 18.1% biologic DMARD, and for the period 2-10 years the numbers were 50.6%, 89.3%, and 62.7%, respectively. At baseline, 70% of the patients had erosions on radiographs. Mean annual change in mTSS was for 0-2 years 3.4, 2-5 years 1.7, and 5-10 years 1.2.
A large proportion of our patients with RA diagnosed and treated in the new biologic treatment era achieved a status of clinical remission or low disease activity and had only a minor increase in radiographic joint damage after the first years of followup.
研究生物治疗时代首个十年中早期类风湿关节炎(RA)患者的短期和长期临床及影像学结局。
1999年至2001年期间,连续纳入在风湿病门诊诊断为早期RA的患者。收集人口统计学特征、疾病活动度、患者报告结局及治疗的数据。在基线以及2年、5年和10年后拍摄手足X线片,并根据Sharp/van der Heijde方法评分,得出改良总Sharp评分(mTSS)。
纳入的94例患者(36例男性和58例女性)的平均基线年龄为50.4岁,症状持续时间为12.3个月;67.8%类风湿因子呈阳性。缓解以及疾病活动度处于低、中、高状态的患者比例在基线时分别为4.3%、1.1%、35.1%和59.6%,在10年时分别为52.1%、20.5%、27.4%和0.0%。在0至2年期间,62.8%的患者使用过泼尼松龙,91.5%使用过合成改善病情抗风湿药(DMARD),18.1%使用过生物DMARD;在2至10年期间,相应数字分别为50.6%、89.3%和62.7%。基线时,70%的患者X线片有侵蚀。mTSS的年均变化在0至2年为3.4,2至5年为1.7,5至10年为1.2。
在新生物治疗时代诊断和治疗的大部分RA患者在随访的头几年后达到临床缓解或低疾病活动度状态,且影像学关节损伤仅轻微增加。